default author photo

Stephane Champiat

Gustave Roussy

Villejuif

France

SCHOLARLY PAPERS

2

DOWNLOADS

82

TOTAL CITATIONS

1

Scholarly Papers (2)

1.

Epigenetic Genes Alterations in Metastatic Solid Tumors: Results from the Prospective Precision Medicine MOSCATO and MATCH-R Trials

Number of pages: 27 Posted: 16 May 2022
Gustave Roussy - Drug Development Department (DITEP), Gustave Roussy, Gustave Roussy, Gustave Roussy - Drug Development Department (DITEP), Gustave Roussy, Gustave Roussy - Drug Development Department (DITEP), Gustave Roussy, Gustave Roussy, Gustave Roussy, Gustave Roussy, Gustave Roussy, Gustave Roussy, Institut d’Hématologie et d’Oncologie Pédiatrique (iHOPe) - Centre Léon Bérard, Gustave Roussy - Drug Development Department (DITEP), Gustave Roussy, Gustave Roussy - Department of Medical Biology and Pathology, Gustave Roussy - Drug Development Department (DITEP), Gustave Roussy - Drug Development Department (DITEP) and Gustave Roussy
Downloads 47 (1,109,210)
Citation 1

Abstract:

Loading...

Epigenetic alterations, Genomics, Precision Medicine, Metastatic solid tumors

2.

Feasibility and clinical relevance of the G-CODE in older adults treated in Phase 1 Clinical Trials at Gustave Roussy

Number of pages: 15 Posted: 15 Oct 2025
Gustave Roussy - Drug Development Department (DITEP), affiliation not provided to SSRN, Gustave Roussy, Gustave Roussy - Drug Development Department (DITEP), Gustave Roussy, Gustave Roussy, Gustave Roussy, Gustave Roussy - Drug Development Department (DITEP), Gustave Roussy - Drug Development Department (DITEP), Gustave Roussy, University of Paris-Saclay - Department of Hematology, Gustave Roussy - Drug Development Department (DITEP), Gustave Roussy - Drug Development Department (DITEP), Gustave Roussy, Gustave Roussy, Gustave Roussy, Gustave Roussy, Gustave Roussy, Université Paris XI Sud - Gustave Roussy Cancer Campus, Gustave Roussy - Drug Development Department (DITEP) and Gustave Roussy
Downloads 35 (1,263,436)

Abstract:

Loading...

G-CODE, geriatric assessment, phase 1 clinical trials, older adults, feasibility, Toxicity